You are here

Article Text

Article menu
Download PDFPDF
Preface
Advances in targeted therapies VII
  1. F C Breedveld,
  2. J R Kalden,
  3. J S Smolen

https://doi.org/10.1136/ard.2005.044339

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The papers brought together in this supplement of the Annals of the Rheumatic Diseases constitute summaries of presentations at the Seventh International Symposium on Advances in Targeted Therapies, which was held on 6–10 April 2005. As such these presentations represent the state of the art on the biology of mechanisms of action and pathophysiology of tumour necrosis factor (TNF) as well as other important mediators of inflammation. Current knowledge on the means and consequences of blocking TNF or other molecules or cellular mechanisms is presented as well.

    We are grateful to Drs Crofford, Furst, Feldmann, …

    View Full Text

    Footnotes

    • ↵* The conference was organised under the sole responsibility of the departments of the universities of Erlangen, Leiden, and Vienna in collaboration with an advisory board consisting of the above mentioned colleagues from departments of rheumatology of several American and European universities. The following companies provided unrestricted educational grants for the organisation of this conference: Abbott Immunology, Amgen, Bristol-Myers Squibb, Centocor, Genentech, Roche, Schering-Plough, UCB, and Wyeth. The pharmaceutical industry had no part in the decisions regarding the specific programme and, with the exception of few observers, participants were selected and solely invited by the organising committee. Several members of the advisory board and the members of the organising committee have obtained experience in the use of TNF and IL-1 blocking compounds in the course of their participation in clinical studies on TNF and IL-1 blocking agents (for which the costs were defrayed by industry).